Optomed PlcStock Exchange Release29 January 2026 at 13:30, Helsinki
Proposal of Optomed's Nomination Board
Optomed's Nomination Board proposes the following to the next Annual General
Meeting:
Number of Board members
The Nomination Board proposes, that the number of members of the Board of
Directors for the term expiring at the end of the Annual General Meeting 2027 is
eight.
Composition of the Board of Directors
The Nomination Board proposes to the Annual General Meeting thatSameer Badlani,
Catherine Calarco, Ty Lee, Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and
Leana Wen are re-elected as Board members, and Kristiina Leppänen is elected as
a new member.
Proposal for the remuneration of the Board of Directors
The Nomination Board proposes to the Annual General Meeting that the annual
remuneration payable to the members of the Board of Directors to be elected at
the Annual General Meeting for the term until the end of the Annual General
Meeting in 2027:
· EUR 40,000 for the Chairman of the Board (increase of EUR 4,000); and
· EUR 20,000 for each Board member (increase of EUR 2,000).
In addition, the Nomination Board proposes that a meeting fee in the amount of
EUR 300 is paid to the committee chairmen and EUR 200 to committee members for
each committee meeting. The Nomination Board proposes that 40 % of the Board
remuneration is paid in Optomed shares and 60 % in cash. The remuneration will
be paid once a year in August, after Optomed's H1 report has been announced.
Nomination Board
Optomed's Nomination Board consists of the following individuals:
· Vesa Vanha-Honko, OP funds
· Petteri Vaarnanen, SP funds
· Ville Kivipelto, Danske funds
Petri Salonen (chairman of Optomed's Board of Directors) serves as the
Nomination Board's expert member and Vesa Vanha-Honko acts as the chairman of
the Nomination Board.
Optomed Plc
Further enquiries
Vesa Vanha-Honko, Chairman of the Nomination Board, vesa@vesasco.fi
Petri Salonen, Chairman of the Board, petri.salonen@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries.